Literature DB >> 32184287

PTPN22 phosphorylation acts as a molecular rheostat for the inhibition of TCR signaling.

Shen Yang1, Mattias N D Svensson1, Nathaniel H O Harder1,2, Wan-Chen Hsieh1, Eugenio Santelli1, William B Kiosses3, James J Moresco4, John R Yates4, Charles C King5, Lin Liu6,7, Stephanie M Stanford1,2, Nunzio Bottini8,2.   

Abstract

The hematopoietic-specific protein tyrosine phosphatase nonreceptor type 22 (PTPN22) is encoded by a major autoimmunity risk gene. PTPN22 inhibits T cell activation by dephosphorylating substrates involved in proximal T cell receptor (TCR) signaling. Here, we found by mass spectrometry that PTPN22 was phosphorylated at Ser751 by PKCα in Jurkat and primary human T cells activated with phorbol ester/ionomycin or antibodies against CD3/CD28. The phosphorylation of PTPN22 at Ser751 prolonged its half-life by inhibiting K48-linked ubiquitination and impairing recruitment of the phosphatase to the plasma membrane, which is necessary to inhibit proximal TCR signaling. Additionally, the phosphorylation of PTPN22 at Ser751 enhanced the interaction of PTPN22 with the carboxyl-terminal Src kinase (CSK), an interaction that is impaired by the PTPN22 R620W variant associated with autoimmune disease. The phosphorylation of Ser751 did not affect the recruitment of PTPN22 R620W to the plasma membrane but protected this mutant from degradation. Together, out data indicate that phosphorylation at Ser751 mediates a reciprocal regulation of PTPN22 stability versus translocation to TCR signaling complexes by CSK-dependent and CSK-independent mechanisms.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2020        PMID: 32184287      PMCID: PMC7263369          DOI: 10.1126/scisignal.aaw8130

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  47 in total

1.  Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue.

Authors:  Edoardo Fiorillo; Valeria Orrú; Stephanie M Stanford; Yingge Liu; Mogjiborahman Salek; Novella Rapini; Aaron D Schenone; Patrizia Saccucci; Lucia G Delogu; Federica Angelini; Maria Luisa Manca Bitti; Christian Schmedt; Andrew C Chan; Oreste Acuto; Nunzio Bottini
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

2.  NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.

Authors:  Marianne R Spalinger; Stephanie Kasper; Claudia Gottier; Silvia Lang; Kirstin Atrott; Stephan R Vavricka; Sylvie Scharl; Tina Raselli; Isabelle Frey-Wagner; Petrus M Gutte; Markus G Grütter; Hans-Dietmar Beer; Emmanuel Contassot; Andrew C Chan; Xuezhi Dai; David J Rawlings; Florian Mair; Burkhard Becher; Werner Falk; Michael Fried; Gerhard Rogler; Michael Scharl
Journal:  J Clin Invest       Date:  2016-11-01       Impact factor: 14.808

3.  Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer.

Authors:  Natela Dushukyan; Diana M Dunn; Rebecca A Sager; Mark R Woodford; David R Loiselle; Michael Daneshvar; Alexander J Baker-Williams; John D Chisholm; Andrew W Truman; Cara K Vaughan; Timothy A Haystead; Gennady Bratslavsky; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Cell Rep       Date:  2017-11-14       Impact factor: 9.423

4.  T cell expressed PKCtheta demonstrates cell-type selective function.

Authors:  B Bauer; N Krumböck; N Ghaffari-Tabrizi; S Kampfer; A Villunger; M Wilda; H Hameister; G Utermann; M Leitges; F Uberall; G Baier
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

5.  The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness.

Authors:  Jinyi Zhang; Naima Zahir; Qiuhong Jiang; Helen Miliotis; Stephanie Heyraud; Xianwang Meng; Baoxia Dong; Gang Xie; Frank Qiu; Zhenyue Hao; Christopher A McCulloch; Edward C Keystone; Alan C Peterson; Katherine A Siminovitch
Journal:  Nat Genet       Date:  2011-08-14       Impact factor: 38.330

6.  Calyculin A, an inhibitor of protein phosphatases, a potent tumor promoter on CD-1 mouse skin.

Authors:  M Suganuma; H Fujiki; H Furuya-Suguri; S Yoshizawa; S Yasumoto; Y Kato; N Fusetani; T Sugimura
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

7.  Identification of a putative regulator of early T cell activation genes.

Authors:  J P Shaw; P J Utz; D B Durand; J J Toole; E A Emmel; G R Crabtree
Journal:  Science       Date:  1988-07-08       Impact factor: 47.728

8.  Protein kinase Calpha (PKCalpha) acts upstream of PKCtheta to activate IkappaB kinase and NF-kappaB in T lymphocytes.

Authors:  Sergey A Trushin; Kevin N Pennington; Eva M Carmona; Susana Asin; Doris N Savoy; Daniel D Billadeau; Carlos V Paya
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

9.  Negative regulation of T-cell receptor signalling by tyrosine protein kinase p50csk.

Authors:  L M Chow; M Fournel; D Davidson; A Veillette
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

10.  Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase.

Authors:  J F Cloutier; A Veillette
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

View more
  4 in total

Review 1.  The rise and fall of anandamide: processes that control synthesis, degradation, and storage.

Authors:  Roger Gregory Biringer
Journal:  Mol Cell Biochem       Date:  2021-03-13       Impact factor: 3.396

Review 2.  Influence of PTPN22 Allotypes on Innate and Adaptive Immune Function in Health and Disease.

Authors:  Lucas H Armitage; Mark A Wallet; Clayton E Mathews
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

3.  SH3-domain mutations selectively disrupt Csk homodimerization or PTPN22 binding.

Authors:  Ben F Brian; Frances V Sjaastad; Tanya S Freedman
Journal:  Sci Rep       Date:  2022-04-07       Impact factor: 4.379

4.  TRAF3 in T Cells Restrains Negative Regulators of LAT to Promote TCR/CD28 Signaling.

Authors:  Tina Arkee; Bruce S Hostager; Jon C D Houtman; Gail A Bishop
Journal:  J Immunol       Date:  2021-06-18       Impact factor: 5.426

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.